press-release · funding
In recognition of the significant strides made in Phase Ia and Phase Ib, the Georgia Research Alliance has awarded a $25,000 Phase Ic grant to Annate Bitherapeutics and the Hajduk Lab at the University of Georgia. This grant will specifically support the advancement of proof-of-concept animal studies, a critical step in the development of their innovative therapeutic against Multiple Myeloma. Read More ›
press-release
The Winship Cancer Institute of Emory University together with the University of Georgia Cancer Center are delighted to unveil the latest recipients of the Winship-UGA Collaborative Pilot Grant. This prestigious, peer-reviewed award fosters collaboration between faculty members from both institutions, driving forward innovative research in the fight against cancer. This year's grant is dedicated to advancing research in ApoL1 targeted therapies, with a focus on combating pancreatic cancer. Read More ›
press-release · presentation
Over 65 ARCS members and guests gathered at the downtown Capital City Club on January 17, 2024, for one of the most exciting General Membership Meetings in recent memory. Former ARCS Scholar Dr. Eric DeJesus spoke about the formation of his new company, Annate BiTherapeutics, Inc. which is based on the research he began as an ARCS scholar at the University of Georgia. Read More ›
press-release · funding
In a significant endorsement of innovative cancer research, the Georgia Research Alliance (GRA) has awarded an additional $25,000 in funding to Annate Bitherapeutics, following a triumphant completion of a Phase Ia project. This investment will bolster the collaborative efforts with the Hajduk Lab at the University of Georgia to advance the development of their promising lead therapeutic for combating Multiple Myeloma. Read More ›
press-release · funding
The Georgia Research Alliance demonstrates its unwavering support for medical innovation by awarding a $25,000 grant to Annate Bitherapeutics in partnership with the Hajduk Lab at the University of Georgia. This strategic funding marks the initiation of Phase Ia in the development of a cutting-edge therapeutic targeting Multiple Myeloma. Read More ›